الصهاينه يخسرون معركة الفياجرا

أعلنت المحكمه في أمريكا أن شركه فايزر كسبت االقضيه المرفوعه على شركة تيفا الصهيونيه بخصوص انتاج الأخيره بدائل للفياجرا , و قالت المحكمه ان ما فعلته تيفا هو انتهاك صريح لحقوق الملكيه الفكريه.

الخبر كاملا:

Pfizer announced Monday that a US district court ruled that Teva cannot market a generic version of Viagra (sildenafil) until a patent on the erectile dysfunction drug expires in October 2019. The “court decision acknowledges Teva’s clear violation of our patent rights,” remarked Amy Schulman, executive vice president and general counsel for Pfizer.

In the ruling, judge Rebecca Beach Smith said “Teva has not shown by clear and convincing evidence that the patent is invalid,” adding that “there is utterly no evidence” to support the Israeli drugmaker’s claim that Pfizer intentionally withheld documents from the US Patent and Trademark Office. Teva had argued in the June trial that the patent was invalid and unenforceable.

Pfizer noted that the decision is subject to appeal, and litigation on the same patent against other companies remains pending.

Bloomberg Industries analyst Asthika Goonewardene said the ruling was a “surprise,” as “the patent was a method-of-use patent, and usually these don’t hold up that well in court for small molecular drugs.” A further patent on Viagra, covering the basic compound, is due to expire next year, but Goonewardene suggested that “the court’s decision to uphold this patent means other filers wanting to enter in 2012 are not likely to do so then.”

According to Leerink Swann, continued market exclusivity for Viagra could boost Pfizer’s earnings by around 3 percent annually between 2013 and 2018. In the first quarter, sales of the drug rose 5.5 percent to $479 million.